www.nature.com/

ORIGINAL ARTICLE Identification of germline susceptibility loci in *ETV6-RUNX1*-rearranged childhood acute lymphoblastic leukemia

E Ellinghaus^{1,19}, M Stanulla^{2,19}, G Richter¹, D Ellinghaus¹, G te Kronnie³, G Cario², G Cazzaniga⁴, M Horstmann⁵, R Panzer Grümayer⁶, H Cavé⁷, J Trka⁸, O Cinek⁹, A Teigler-Schlegel¹⁰, A ElSharawy¹, R Häsler¹, A Nebel¹, B Meissner², T Bartram², F Lescai¹¹, C Franceschi¹², M Giordan³, P Nürnberg¹³, B Heinzow^{14,15}, M Zimmermann¹⁶, S Schreiber^{1,17,18,19}, M Schrappe^{2,19} and A Franke^{1,19}

Acute lymphoblastic leukemia (ALL) is a malignant disease of the white blood cells. The etiology of ALL is believed to be multifactorial and likely to involve an interplay of environmental and genetic variables. We performed a genome-wide association study of 355 750 single-nucleotide polymorphisms (SNPs) in 474 controls and 419 childhood ALL cases characterized by a t(12;21)(p13;q22) – the most common chromosomal translocation observed in childhood ALL – which leads to an *ETV6-RUNX1* gene fusion. The eight most strongly associated SNPs were followed-up in 951 *ETV6-RUNX1*-positive cases and 3061 controls from Germany/Austria and Italy, respectively. We identified a novel, genome-wide significant risk locus at 3q28 (*TP63*, rs17505102, $P_{CMH} = 8.94 \times 10^{-9}$, OR = 0.65). The separate analysis of the combined German/Austrian sample only, revealed additional genome-wide significant associations at 11q11 (*OR8U8*, rs1945213, $P = 9.14 \times 10^{-11}$, OR = 0.69) and 8p21.3 (near *INTS10*, rs920590, $P = 6.12 \times 10^{-9}$, OR = 1.36). These associations and another association at 11p11.2 (*PTPRJ*, rs3942852, $P = 4.95 \times 10^{-7}$, OR = 0.72) remained significant in the German/Austrian replication panel after correction for multiple testing. Our findings demonstrate that germline genetic variation can specifically contribute to the risk of *ETV6-RUNX1*-positive childhood ALL. The identification of *TP63* and *PTPRJ* as susceptibility genes emphasize the role of the *TP53* gene family and the importance of proteins regulating cellular processes in connection with tumorigenesis.

Leukemia (2012) 26, 902-909; doi:10.1038/leu.2011.302; published online 11 November 2011

Keywords: genome-wide association study; childhood acute lymphoblastic leukemia; TP63

INTRODUCTION

Acute lymphoblastic leukemia (ALL) is characterized by the malignant clonal proliferation of lymphoid cells that are blocked at an early stage of differentiation. More than 60% of patients diagnosed with ALL are children below the age of 15 years.¹⁻³ The annual incidence rates of childhood ALL vary worldwide between one and four new cases per 100 000 children younger than 15 years, with a peak incidence at about 2–5 years of age.³⁻⁵

As for most other human malignancies not underlying a clear hereditary genetic trait, the etiology of childhood ALL is believed to be multifactorial, including environmental risk factors like radiation and other toxins as well as genetic variables.^{6,7} Different subtypes of childhood ALL are classifiable according to either immunophenotypic (for example, precursor B-cell vs T-cell lineage ALL) or a constantly growing number of recurrent somatic genetic aberrations that have been characterized during the last decades.^{1,2,8,9} The two major genetic subtypes of childhood ALL are characterized by either hyperdiploidy (>50 chromosomes per leukemic cell) or the chromosomal translocation t(12;21)(p13;q22) leading to an *ETV6-RUNX1* (*TEL-AML1*) gene fusion.¹⁰ Hyperdiploid and *ETV6-RUNX1*-rearranged childhood ALL account for ~25% and 22% of the entire childhood ALL population, respectively.

A minority of childhood ALL cases (<5%) is related to specific genetic conditions such as Down's syndrome or disorders associated with impaired DNA repair capacities (for example, ataxia teleangiectasia, Nijmegen breakage syndrome or Bloom's

¹Institute of Clinical Molecular Biology, Christian-Albrechts-University Kiel, Keil, Germany; ²Department of Pediatrics, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany, on behalf of the German Berlin-Frankfurt-Münster Study Group for Treatment of Childhood Acute Lymphoblastic Leukemia; ³Department of Pediatrics, Laboratory of Pediatric Hematology/Oncology, University of Padua, Padua, Italy; ⁴M. Tettamanti Research Center, Children's Hospital, University of Milan-Bicocca, Monza, Italy; ⁵Clinic of Pediatric Hematology and Oncology, University Medical Center, and Research Center Children's Cancer Center, Hamburg, Germany; ⁶St Anna Children's Hospital and Children's Gancer Research Institute, Vienna, Austria; ⁷Department of Genetics, Hôpital Robert Debré, Paris, France; ⁸Department of Pediatric Hematology/Oncology, Second Faculty of Medicine, Charles University Prague, Prague, Czech Republic; ⁹Department of Pediatrics, Second Faculty of Medicine, Charles University Prague, Prague, Czech Republic; ⁹Department of Pediatrics, Second Faculty of Medicine, Charles University Prague, Prague, Czech Republic; ¹⁰Oncogenetic Laboratory, Department of Experimental Pathology, University of Bologna, Bologna, Italy; ¹³Cologne Center for Genomics, University of Cologne, Cologne, Germany; ¹⁴State Social Services Agency Schleswig-Holstein, Kiel, Germany; ¹⁵University of Notre Dame, Sydney Medical School, Sydney, Australia; ¹⁶Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany; ¹⁷Department of General Internal Medicine, University Hospital Schleswig-Holstein, Christian-Albrechts-University Kiel, Kiel, Germany and ¹⁸Popgen Biobank, University Hospital Schleswig-Holstein, Christian-Albrechts-University Kiel, Schittenhelmstr. 12, D-24105 Kiel, Germany. Errorespondence: Professor Dr rer. nat. A Franke, Institute of Clinical Molecular Biology, Christian-Albrechts-University Kiel, Schittenhelmstr. 12, D-24105 Kiel, Germany.

or Professor Dr med. M Stanulla, Department of Pediatrics, University Hospital Schleswig-Holstein, Campus Kiel, Arnold-Heller-Str. 3, D-24105 Kiel, Germany. E-mail: martin stanulla@uk-sh de

¹⁹These authors contributed equally to this work.

Received 9 June 2011; revised 3 September 2011; accepted 21 September 2011; published online 11 November 2011

syndrome).^{6,7} Recently, two genome-wide association studies (GWAS) on childhood ALL performed in the UK and the US have identified 13 susceptibility loci.^{11,12} The UK study screened around 291 000 single-nucleotide polymorphisms (SNPs) in 907 ALL cases (a mixture of different subtypes) in a meta-analysis without independent replication while the US study investigated nearly 308 000 SNPs in 317 ALL cases (also a mixture) after quality control. The two highest scoring loci were detected by both studies and subsequently verified by others:¹³ *IKZF1*, a transcription regulator of lymphoid cell differentiation, and *ARID5B* a member of the AT-rich interaction domain family of transcription factors.

We report here the results of a genome-wide association study conducted with patients displaying a subtype of childhood ALL characterized by the chromosomal translocation which leads to an *ETV6-RUNX1* gene fusion. Thus, to the best of our knowledge, our study is the first genome-wide approach to susceptibility loci primarily addressing one of several well-defined and specific subgroups of the heterogenous disease entity 'childhood ALL'.

PATIENTS AND METHODS

Recruitment of patients and healthy controls

Samples were organized in panels that corresponded to the successive steps of the present study. All individual panels (A-D, Supplementary Table S1) were independent from each other.

All patients included in panel A, 206 patients from panel B, and all patients from panels C and D were enrolled into the Austrian-German-Italian-Swiss multicenter clinical trial AIEOP-BFM ALL 2000 on treatment of childhood ALL after informed consent had been obtained. Patients were diagnosed and treated at one of 121 participating study centers in Austria, Germany and Italy between 1999 and 2008. 200 ALL patients from panel B were enrolled into two subsequent clinical trials of the German COALL study group, COALL-06-97 and COALL-07-03 between 1997 and 2008 at 19 German treatment centers. To generate the extended panel B with 664 patients, the 406 patients from panel B were complemented with an additional 258 patients enrolled in the years 2009 and 2010 into the Austrian-German-Italian-Swiss multicenter clinical trials AIEOP-BFM ALL 2000 or its predecessor, the ongoing trial AIEOP-BFM ALL 2009 after informed consent had been obtained. Diagnosis was based on cytomorphology (FAB criteria) and cytochemistry when $\geq 25\%$ of lymphoblastic cells were present in the bone marrow, or when lymphoblasts were present in the peripheral blood or cerebrospinal fluid. Flow cytometric immunophenotyping was performed according to consensus protocols based on the guidelines proposed by the European Group for the immunological characterization of Leukemias. The presence or absence of ETV6-RUNX1, BCR-ABL and MLL-AF4 fusion gene transcripts was analyzed by a multiplex PCR assay enabling the detection of M-BCR-ABL, m-BCR-ABL, ETV6-RUNX1 and MLL-AF4 fusion transcripts in a single PCR reaction. Positive results were confirmed by interphase fluorescence in situ hybridization in the majority of the patients. Written, informed consent was obtained from all study participants or their legal guardians to use spare diagnostic specimens for research purposes and all protocols were approved by the respective institutional ethical review committees.

Bone marrow samples were obtained at initial diagnosis and at consecutive follow-up time points during therapy, mainly after induction and consolidation. Mononuclear cells were isolated by Ficoll-Paque gradient centrifugation (Pharmacia, Freiburg, Germany) from bone marrow samples followed by extraction of high-molecular weight DNA according to standardized protocols. Quality and quantity of genomic DNA was determined by spectrophotometry. In the present study only remission DNA obtained at follow-up time points after induction or consolidation was analyzed.

The German healthy control individuals of panel A and B were obtained from the popgen biobank.¹⁴ The healthy Italian controls of panel C were recruited through the blood bank of the San Gerardo Hospital at Monza, Italy. Written and informed consent was obtained from all study



participants and all protocols were approved by the institutional ethical review committees of the participating centers. To account for their heterogeneous sources, all DNA samples were first quality-controlled by gel electrophoresis.

SNP genotyping for genome-wide screening

The genotyping for the GWAS samples (panel A), which was part of the German NGFN GWAS initiative funded by the NGFN, was performed as a service project by Affymetrix (South San Francisco, CA, USA) using the genome-wide human SNP array 5.0. (500 k) with 443 816 markers. The array is based on an assay termed whole-genome sampling analysis developed for highly multiplexed SNP genotyping of complex DNA. This method reproducibly amplifies a subset of the human genome through a single primer amplification reaction using restriction enzyme digested and adapter-ligated human genomic DNA.

In brief, 5 μ l of genomic DNA samples at 50 ng/ μ l were aliguoted to the corresponding wells of two 96-well plates. The first run of samples was processed as an entire plate. In the lab, transfers were made with a 12-channel pipette, reducing the risk of sample tracking errors. One plate was digested with Nsp I and the other plate was digested with Sty I. The reaction was incubated at 37 °C for 2 h and at 65 °C for 20 min to deactivate the enzyme. The digested DNA was then ligated to their respective Nsp I adaptor and Sty I adaptor. The ligated product was then PCR-amplified using a common primer. Both Nsp I PCR product and Sty I PCR product were combined, and then purified by ethanol precipitation in combination with membrane filter plate. Purified PCR product was further fragmented with DNase I and then labeled with biotin. Labeled DNA was combined with hybridization mix and then injected into array. Arrays were hybridized for 18-22 h at 50 °C. DNA samples were recovered from arrays and washed and stained by using Affymetrix FS450 fluidic stations. Stained arrays were scanned using Affymetrix GeneChip Scanner 3000 7G.

Raw image files were converted into cel-files by Affymetrix genotyping console. A preliminary QC call rate of 86% was used to pass arrays for further data analysis. Passed arrays were clustered in the same batches which were processed together in the lab. Genotypes were assigned using the BRLMM-p algorithm. There were 12 positive control samples run in each project. The positive controls were from a CEPH trio family: NA12740 - daughter (six repeats), NA12750 - father (four repeats), and NA12751 - mother (four repeats). This set of controls allowed to calculate experimental reproducibility, trio accuracy and HapMap concordance. The average call rate was above 96%, and the average BRLMM-p call rate, average reproducibility (controls), average HapMap concordance (controls) and average trio accuracy were above 99%.

Samples with more than 5% missing genotypes, who showed excess genetic dissimilarity to the other subjects or who showed evidence for cryptic relatedness to other study participants (Supplementary Figure S1) were removed. These quality control measures left 419 *ETV6-RUNX1*-positive ALL patients and 474 healthy control samples for inclusion in screening panel A. All gender assignments could be verified by reference to the proportion of heterozygous SNPs on the X chromosome. Before analysis, all SNPs that had a low genotyping rate (<95% in cases or controls), were monomorphic or rare (minor allele frequency <2% in cases or controls), or deviated from Hardy-Weinberg equilibrium in the control sample ($P_{HWE} \leq 0.001$) were excluded (n = 88.066; 19.8% of all SNPs).

SNPlex, TaqMan and Sequenom genotyping

All downstream genotyping (panels B through D) was performed with SNPlex and TaqMan technologies (Applied Biosystems, Foster City, CA, USA) or the Sequenom platform using an automated laboratory setup and all process data were written to and administered by a database-driven laboratory information management system.

Of 100 selected SNPs 87 SNPs passed quality control in both replication samples. These SNPs had a high call rate (>95% in cases or controls), were not monomorphic or rare (minor allele frequency >1% in cases or controls) and did not deviate from Hardy-Weinberg equilibrium in the control population (P_{HWE} >0.001).

904 Mutation detection

Amplicons were generated using the following touchdown PCR program: 95 °C for 12 min, (95 °C for 30 s, T_m for 30 s, 72 °C for 30 s) \times 16 cycles (td –0.5 °C), (95 °C for 30 s, T_m for 30 s, 72 °C for 30 s) \times 19 cycles, 72 °C for 10 min and 10 °C for ∞ .

Sequencing of genomic DNA was performed using BigDye Terminator v3.1 chemistry (Applied Biosystems) and an ABI3730 capillary sequencer (Applied Biosystems) according to manufacturer protocols. Traces were inspected for SNPs and InDels using novoSNP v2.03.

Statistical analyses

Our screening panel A had 80% power to detect a variant with an odds ratio of 1.48 or higher at the 5% significance level, assuming a frequency of the disease-associated allele of at least 30% in controls (calculated with PS Power and Sample Size v3.0.12¹⁵). For subsequent statistical analyses, we used a data set that passed stringent quality control filters (see section SNP genotyping for genome-wide screening) resulting in 355750 SNPs genotyped in 419 cases and 474 healthy controls. The total genotyping rate across these samples was 99.8%. We found minimal evidence for an overall inflation of the test statistics due to population stratification with a moderate genomic control value of $\lambda_{GC} = 1.14$. Furthermore, a multidimensional scaling analysis showed genuine European ancestry of panel A and identity-by-state analysis revealed neither non-European 'outliers' nor cryptically related individuals after quality control (Supplementary Figure S1). Genome-wide association analyses were conducted with gPLINK v2.050 in combination with PLINK v1.07.16 GWAS data were also analyzed with R statistical environment version 2.10.0.

After the initial comparison of case-control frequencies (Supplementary Figure S2), we pruned the SNP list for redundancy due to linkage disequilibrium (using the 'clump' command in PLINK) and visually inspected the cluster plots of the obtained index SNPs with a *P*-value $< 2 \times 10^{-7}$ (Supplementary Figure S3). The 100 most strongly associated SNPs were subsequently selected for replication analysis and genotyped in the German replication panel B (consisting of 406 cases and 1682 controls) and the Italian replication panel C (comprising 287 cases and 579 controls). After quality control, we excluded 12 follow-up SNPs with a call rate less than 95% in cases or controls and one SNP with significant deviation from Hardy-Weinberg equilibrium in the controls (P < 0.001). To take the different geographic origin of the two replication panels into account, we used a Cochran - Mantel - Haenszel test (P_{CMH}) and a Breslow - Day test for odds ratio heterogeneity (P_{BD}) in both the combined analysis of replication panels B and C and in the overall study sample (panels A through C) (Supplementary Table S2). The eight SNPs with a *P*-value $< 5 \times 10^{-7}$ in the combined analysis of panels A and B or A through C were additionally genotyped in 258 ETV6-RUNX1-positive ALL cases and 800 healthy controls from Germany (extended replication panel B: 664 cases and 2482 controls).

Imputation

The software package BEAGLE v3.1.1 ^(ref. 17) was used to impute the genotypes of autosomal SNPs based on the 1000 Genomes data. As input for imputation, we used only SNPs on the Affymetrix platform that passed quality control. To take imputation uncertainty into account, association analysis between the phenotype and the dosage data (expected allele counts) was performed using PLINK's logistic regression framework for dosage data (with the 'dosage' command).

Plotting

Regional association plots were generated by using a modified version of deBakker's R script. SNPs are represented with their corresponding *P*-values (on $-\log_{10}$ scale) on the vertical axis as a function of physical position. Single-marker association analysis was performed using PLINK's standard case-control allelic test (with the 'assoc' command) and study SNPs as well as imputed SNPs were used as input. Physical positions on chromosomes are based on NCBI build 36. Estimated recombination rates from phased haplotypes in HapMap release 22 (build 36) were downloaded from the HapMap website, gene annotations were downloaded from the UCSC genome browser (using build 36 coordinates).

Leukemia (2012) 902 - 909

eQTL analysis

Expression data of *TP63* (*TP73L*), *PTPRJ* and *INTS10* (*FLJ10569*) in EBVtransformed lymphoblastoid cell lines from the HapMap samples was available from the GENEVAR project,¹⁸ and expression in the n = 60 CEU parents was correlated to SNP genotypes, using linear regression in the web-based tool SNPEXP v1.1. (http://app3.titan.uio.no/biotools/tool.php? app = snpexp).

RESULTS

Associations with ETV6-RUNX1 subtype of childhood ALL

Novel significant disease associations that withstood Bonferroni correction (adjusted significance threshold $\alpha = 5.75 \times 10^{-4}$ (0.05/ 87)) in the combined analysis of replication panels B and C were obtained for rs17505102, an intronic SNP in the gene encoding the tumor protein p63 isoform 3 (*TP63*; also known as tumor protein p73-like: *TP73L*) on chromosome 3q28 ($P_{CMH} = 4.87 \times 10^{-7}$, OR = 0.63, 95% CI = 0.52-0.75) and for the intronic SNP rs3942852, located in the gene *PTPRJ* (protein tyrosine phosphatase, receptor type, J) on chromosome 11p11.2 ($P_{CMH} = 2.54 \times 10^{-4}$, OR = 0.77, 95% CI = 0.68-0.89) (Table 1 and Figure 1). Although the associations of these loci with *ETV6-RUNX1*-positive ALL did not achieve genome-wide significance (conventional level of $P < 5.0 \times 10^{-8}$) in the discovery panel, we obtained genome-wide significance for rs17505102 ($P_{CMH} = 8.94 \times 10^{-9}$) within the *TP63* gene in the overall sample of panels A through C comprising 1370 *ETV6-RUNX1*-positive ALL cases and 3535 healthy controls. For rs3942852, the combined analysis of the overall sample yielded $P_{CMH} = 1.00 \times 10^{-6}$.

As the initial screening (discovery panel A) was performed with German samples only, we additionally analyzed the follow-up SNPs in the German/Austrian replication panel B exclusively to identify potential loci that are more specific for northern Europeans as compared with those that confer susceptibility in the European population in general. Apart from the two novel shared susceptibility loci (rs17505102 and rs3942852), we found another two associated SNPs that remained significant after correction for multiple testing: rs1945213 on chromosome 11g11 within the OR8U8 gene (olfactory receptor, family 8, subfamily U, member 8; $P = 1.63 \times 10^{-7}$) and rs920590 on 8p21.3 24 kb upstream of INTS10 (Integrator complex subunit 10: $P = 1.05 \times 10^{-5}$). Furthermore, three of these associations (rs17505102, rs1945213 and rs920590) were genome-wide significant in the combined analysis of the German/Austrian panels A and B comprising 1083 cases and 2956 controls. For rs3942852 we obtained a *P*-value of 4.95×10^{-7} in the combined analysis (Table1 and Figure 1). Of the newly identified susceptibility loci especially the PTPRJ gene and the tumor protein 63 are very interesting candidates, taking account of their functional role and strong homology with the tumor suppressor gene TP53, respectively. As the marker rs17505102 is located in the first intron of the TP63 gene, we sequenced exons 1–3 in 47 ALL cases to determine whether the lead SNP might tag one or more potential causative coding polymorphisms via linkage disequilibrium. However, we did not identify any coding SNP in these regions. Additionally, we checked NCBI's dbSNP¹⁹ build 134 for reported and validated, non-synonymous coding SNPs (≥1% frequency) within the TP63 gene, but found no SNP entries satisfying these criteria.

Using a publicly available resource (web-based tool SNPexp v1.1²⁰), we were not able to identify any significant correlation – so-called eQTL effect – between the genotypes at the lead SNPs rs17505012, rs1945213, rs3942852 and rs920590 and the expression levels of the nearby located genes (*TP63, PTPRJ* and *INTS10*) in EBV-transformed lymphoblastoid cell lines from the HapMap samples (available from the GENEVAR project¹⁸). For *OR8U8* no expression data were available. However, it is noteworthy that the SNP rs3942852, located in the first intron of the *PTPRJ* gene,

Chr position (bp)	di questo ID	Nearby genes (relative position)	A1 A2	panel / Ger. ETV6-Ri 479 c 419	panel A - GWAS Germany ETV6-RUNX1-pos. 479 controls 419 cases	panel Ge. 2482 2482	panel B _{oxtended} Germany ETV6 - RUNX1-pos. 2482 controls 664 cases	pane. G€ ETV6 - I 2956 108	panel A + B _{ext.} Germany ETV6 - RUNX1-pos. 2956 controls 1083 cases	ра 1 ЕТV6 - R 579 (panel C Italy ETV6 - RUNX1-pos. 579 controls 287 cases		panel B _{ext} + C Replication ETV6 - RUNX1-pos. 3061 controls 951 cases	C pos.	panel A + B _{ext} + C Combined analysis ETV6- RUNX1-pos. 3535 controls 1370 cases	B _{ext.} + C 1 analysis NX1-pos. mtrols cases
				AF _{A1} contr. AF _{A1} case	Pccs	AF _{A1} contr. AF _{A1} case	PccA	AF _{A1} contr. AF _{A1} case	P _{CCA}	AF _{A1} contr. AF _{A1} case	P _{CCA}	Рсмн	P _{BD}	OR (95% CI)	Рамн	P_{BD}
3	rs17505102	TP63	U	0.18	1.15×10^{-04}	0.14	$\textbf{1.50}\times \textbf{10}^{-06}$	0.15	2.96×10^{-08}	0.08	0.11	$\textbf{4.87}\times\textbf{10}^{-07}$	0.44	0.63 (0.52-0.75)	8.94×10^{-09}	0.57
190 884 470 11	rs1945213	(Within gene) OR8U8	ن ں ق	0.11 0.33	5.82×10^{-05}	0.09	$\textbf{1.63}\times \textbf{10}^{-07}$	0.10 0.31	$9.14 imes 10^{-11}$	0.06	0.32	$\textbf{4.27}\times 10^{-05}$	$\textbf{4.13}\times 10^{-04}$	0.78 (0.69 - 0.88)	$3.89 imes10^{-08}$	$2.21\times \mathbf{10^{-04}}$
55 932 247 11 48 071 665	rs3942852	(Within gene) PTPRJ (Within gene)	บบษ	0.24 0.24 0.17	$1.58 imes 10^{-04}$	0.23 0.21 0.17	$\textbf{1.67}\times\textbf{10}^{-04}$	0.24 0.22 0.17	4.95×10^{-07}	0.24 0.18 0.17	0.43	$\textbf{2.54}\times \textbf{10}^{-04}$	0.21	0.77 (0.68 - 0.89)	$1.00 imes 10^{-06}$	0.14
14 75 773 104	rs7156960	C140rf118 (+ 50kb)	- o (0.52	$9.16 imes 10^{-06}$	0.47	$2.54 imes 10^{-03}$	0.48	$3.74 imes10^{-06}$	0.41	0.10	$6.05 imes 10^{-04}$	0.89	0.83 (0.75-0.92)	$1.09 imes 10^{-06}$	0.58
15 90.458.377	rs207954 ^a	(dx) vc ±) SLCO3A1 (Within gene)	U – U	0.29 0.21	1.24×10^{-04}	0.28 0.25	60.0	0.28 0.28 0.23	$6.58\times\mathbf{10^{-05}}$	0.26 0.26	$5.60 imes10^{-03}$	$2.45 imes 10^{-03}$	0.22	0.80 (0.70-0.93)	$1.35\times\mathbf{10^{-06}}$	0.61
8 19695441	rs920590	INTS10 (±50kb)	υF	0.29	$5.19 imes10^{-05}$	0.31	$1.05 imes 10^{-05}$	0.31	$6.12 imes10^{-09}$	0.45	0.36	1.32×10^{-03}	$1.87 imes 10^{-03}$	1.19 (1.07 - 1.33)	$2.22 imes 10^{-06}$	$5.54 imes10^{-04}$
4	rs282708 ^a	-	. < (0.39	$3.91 imes 10^{-05}$	0.41	0.03	0.40	$5.41 imes10^{-06}$	0.46	0.42	0.03	0.51	1.15 (1.01 - 1.30)	$1.38 imes 10^{-05}$	0.12
19	rs2910225 ^a	CCDC130	וטפ	0.42	1.02×10^{-05}	0.36	0.16	0.37	6.97×10^{-04}	0.30	0.01	$9.83\times\mathbf{10^{-03}}$	0.23	0.84 (0.74-0.96)	$3.23\times\mathbf{10^{-05}}$	0.54
13 727 957 15	rs11857366 ^a	(Within gene) IGF1R	- <	0.32 0.37	5.98×10^{-05}	0.33 0.40	0.08	0.32 0.39	7.01×10^{-05}	0.24 0.42	0.16	0.02	0.98	1.15 (1.02 - 1.30)	$3.41 imes 10^{-05}$	0.45
97 081 324 5	rs7734914 ^a	(Within gene) -	ט <	0.46 0.40	1.32×10^{-05}	0.43 0.44	0.42	0.45 0.43	6.09×10^{-04}	0.45 0.46	0.03	$\textbf{4.71}\times\textbf{10}^{-02}$	0.21	1.13 (1.00 - 1.28)	4.81×10^{-05}	0.82
10 085 335 6	rs7738636		υ U	0.50 0.26	$9.84 imes 10^{-05}$	0.45 0.23	0.02	0.48 0.24	$7.44 imes 10^{-05}$	0.52 0.16	0.46	0.02	0.67	0.85 (0.75-0.97)	$8.54\times\mathbf{10^{-05}}$	0.35
77 846 527 1	rs343604 ^a	KCNA3	< ⊢	0.18 0.07	$8.39 imes 10^{-05}$	0.20 0.09	0.03	0.20 0.08	$1.19 imes10^{-06}$	0.15 0.08	0.67	0.14	0.08	0.84 (0.67 - 1.06)	$9.25 imes 10^{-05}$	$1.46 imes 10^{-03}$
111 060 293	r conceoa	(土 50 kb) p 5003	0 <	0.03	2 61 \ 10 ⁻⁰⁵	0.06	A A6 ~ 10 ⁻⁰³	0.05	2 A7 ∨ 10 ^{−06}	0.09 55 0	0.45	900	00	101 26 01 20 0	10-01 × 30 1	2 £5 ∨ 10 ^{−03}
o 109 041 474	700000051	(Within gene)	ر ک	0.22	01 × 10.0	0.23	4,40 × 10	0.22	7:07 × 10	0.25	0.40	0.0	70.0	(10.1 - 0.70) 10.0	01 × 0C.1	01 × co.2
13 38 845 574	rs7336133 ^a	LHFP (Within gene)	ئ ∢	0.38 0.29	$3.53 imes10^{-05}$	0.32	0.42	0.34	$6.01 imes 10^{-03}$	0.34 0.28	0.01	0.03	0.13	0.86 (0.75 - 0.98)	$2.71 imes10^{-04}$	0.39
1	rs17423910	PDE48	0.0	0.14	$2.18\times\mathbf{10^{-06}}$	0.17	0.01	0.17	6.37×10^{-06}	0.23	0.43	0.11	0.05	1.11 (0.98 - 1.27)	$3.07\times\mathbf{10^{-04}}$	0.01
60 40 1 09/ 6	rs6901152 ^a	(Within gene) A <i>IG1</i>	∢ ⊢	0.23 0.46	$3.19 imes10^{-05}$	0.20 0.42	$\textbf{4.63}\times\textbf{10}^{-03}$	0.21	4.71×10^{-06}	0.21	0.37	60.0	0.01	0.90 (0.79-1.02)	$4.19 imes 10^{-04}$	2.12×10^{-03}
143 700 705 4	rs936094 ^a	(Within gene) <i>RXFP1</i>	υυ	0.36 0.15	$9.42 imes 10^{-06}$	0.36 0.17	0.01	0.36 0.17	$1.43 imes 10^{-06}$	0.47 0.25	0.28	0.24	0.02	1.09 (0.94 - 1.27)	$4.74 imes 10^{-04}$	$6.48 imes 10^{-04}$
159 663 764 3	75AA575A	(Within gene)	⊢ ر	0.23	1 87 ~ 10 ⁻⁰⁷	0.21	7 07 ~ 10 ⁻⁰³	0.22	A 60 ~ 10 ⁻⁰⁶	0.23	KC O	0 13	600	(10 (008 - 1 24)	5 08 < 10 ⁻⁰⁴	$1.62 ~ 10^{-03}$
55 782 295		(Within gene)	γ⊢	0.28	01 × 70'1	0.26		0.27		0.29	17.0	21.0	7000			01 × 70'1
14 58 908 882	rs4901921 ^ª	<i>DAAM1</i> (± 10 kb)	⊢υ	0.52 0.43	1.48×10^{-57}	0.47 0.45	0.29	0.48 0.44	5.41×10^{-03}	0.40 0.35	0.04	0.04	0.32	0.88 (0.78 - 0.99)	6.45×10^{-01}	0.66
6 73 500 100	rs6910780 ^a	<i>KCNQ5</i> (Within gene)	⊢υ	0.16 0.23	$1.47 imes 10^{-04}$	0.19 0.23	0.01	0.18 0.23	$3.89 imes10^{-05}$	0.22 0.21	0.64	0.09	0.06	1.13 (0.98 - 1.31)	$9.29 imes 10^{-04}$	0.02
Abbreviatio genotyped and C: 2735 respectively $P_{BD} > 0.05$). analysis of r SNPs are sh denotes the analysis usir B and C). Co B and C). Co disease asso replication a analysis (con	ns: AF, allele n the additi controls ar controls ar (panels B a Additionally anels A and wm in Supt vwn in Supt rare allele k g an allele k g an allele k iumn P_{BD} lis ciation. Cor reiton. Cor reiton a Phylight abinght	Abbreviations: AF, allele frequency; Chr, chromosome; Cl, confidence interval; GWAS, genome-wide association study; OR, odds ratio; SNP; single-nucleotide polymorphism. ^a The 12 SNPs that were not genotyped in the additional samples but only in the non-extended panel B: 1682 controls and 406 cases; panels A and B: 2156 controls and 825 cases; panels B and C: 2261 controls and 693 cases; panels A, B and C: 2735 controls and 1112 cases. 100 SNPs were selected for genotyping in two independent replication panels of <i>ETV6-RUNX1</i> -positive cases and healthy controls from Germany/Austria and Italy, respectively, (panels B and C). Data are shown for the 20 SNPs that were nominal significant either in replication panels of <i>ETV6-RUNX1</i> -positive cases and healthy controls from Germany/Austria and Italy, respectively, (panels B and C). Data are shown for the 20 SNPs that were nominal significant either in replication panels of <i>ETV6-RUNX1</i> -positive cases and healthy controls from Germany/Austria and Italy. Pbio 50.05. Additionally, these 20 SNPs were also genotyped in 326 German <i>ETV6-RUNX1</i> -positive ALL cases (panel D) (Supplementary Table S3). The eight SNPs with a <i>P</i> -values of <i>P</i> -ord in the combined analysis of panels A and B or A through C were also genotyped in 226 German <i>ETV6-RUNX1</i> -positive ALL cases (panel D) (Supplementary Table S3). The eight SNPs with a <i>P</i> -values of Panel S analysis of panels A, B and C. Nucleotion analysis of panels A and B or A through C are also genotyped in 226 German <i>ETV6-RUNX1</i> -positive ALL cases (panel D) (Supplementary Table S2. SNPs are ranked according to the <i>P</i> -value obtained in the combined analysis of panels A, B and C. Nucleotion (pb)) refer to NCBIs build 36, A1 denotes the rare allele while A2 is the common allele. The respective panels of analysis of panels A, B and C. Nucleotion analysis (panels B and C). Colum <i>P</i> _{8D} lists the asymptotic <i>P</i> -values of arefore a state of <i>P</i> -co. Odds ratios (OR) and 95% confidence intervals (95% C) for carriership of the allele A1 are	chroi tit only 00 SN 00 SN 00 SN chown c were c e degr c P-val (P _{CMH} and B	mosome; CI in the nor- Ps were sels for the 20 5 also genoty NPs are ran NPs are ran n allele. The ee of freedd (ues of a Bre ues of a Bre ues of a Bre variants that r	, confidence extended par ected for gen sNPs that wer fped in 326 G ked accordin ked accordin srespective al m) are listed chran - Mantel	interval; G interval; G iotyping in iotyping in e nominal ierman ET additional g to the P - g to the P - flele freque t for heter if for heter if for heter if for heter if for heter if for heter afte	WAS, genom t controls and t two indepen significant ei <i>KG</i> - <i>RUNX1</i> -ne <i>ETVG</i> - <i>RUNX1</i> -ne <i>ETVG</i> - <i>RUNX1</i> -ne <i>erces</i> are shu ds ratios (OR) ogeneity. A si l test statistic	e-wide ass addent replination of the cases and the cases and the cases adding the case and in the case and per all and 95% c ignificant F (one deguination or multiple	ociation stud ociation panels A an lication panel lication pane - cases (panel LL cases and ombined ane ele A1 in com confidence int confidence indica ree of freedo z testing (P_{CM}	y; OR, odds d B: 2156 c.(a d E: 2156 c.(I B ($P_{CCA} < 0$ I D) (Supple 800 controli. Ilysis of pan trols and ca trols and ca trol and ca	i ratio; SNP, s ontrols and f ZUNX7-positik 2050 or in the mentary Tab mentary Tab ses, respectik ses, respectik and for carrie and heterorg wn. Significal	ingle-nucleot is25 cases; par le cases and l ie S3). The ei ie S3)	ide polymor lels B and C: healthy cont pplication an ght SNPs wi transed 664 cc transed 660 cc	terval; GWAS, genome-wide association study; OR, odds ratio; SNP, single-nucleotide polymorphism. ^a The 12 SNPs that were not Al B: 1682 controls and 406 cases; panels A and B: 2156 controls and 825 cases; panels B and C: 2261 controls and 693 cases; panels A, B syping in two independent replication panels of <i>ETV6-RUNX1</i> -positive cases and healthy controls from Germany/Austria and Italy, nominal significant either in replication panels of <i>ETV6-RUNX1</i> -positive cases and healthy controls from Germany/Austria and Italy, mominal significant either in replication panel B ($P_{CCA} < 0.05$) or in the combined replication analysis of panels B and C ($P_{CMH} < 0.05$ and trana <i>ETV6-RUNX1</i> -negative ALL cases (panel D) (Supplementary Table S3). The eight SNPs with a <i>P</i> -value $< 5 \times 10^{-7}$ in the combined ditional <i>ETV6-RUNX1</i> -positive ALL cases and 800 controls from Germany (panel B _{extended} 664 cases and 2482 controls). Results of al 100 to the <i>P</i> -value obtained in the combined analysis of panels A, B and C. Nucleotide positions (position (bp)) refer to NCBI's build 36. A1 the frequencies are shown for allele A1 in controls from Germany (panel B _{extended} 664 cases and 2482 controls). Results of all P_{CCA} . GORs and 2608 and 95% confidence intervals (95% CI) for carriership of the allele A1 are shown for the replication analysis (panels for herogeneity. A significant <i>P</i> -value indicates a significant heterogeneity between replication panels in terms of the odds ratio of the Haenszel test statistic (one degree of freedom) are shown. Significant <i>P</i> -values ($P_{CCA} < 0.05$ or $P_{CMH} < 0.05$ [only if $P_{BD} > 0.05$]) of the cant after correction for multiple testing (P_{CMH} of panels B and C) as well as genome-wide significantly associated SNPs in the combined to the <i>P</i> -value significant <i>P</i> -values of freedom) are shown. Significant <i>P</i> -values ($P_{CCA} < 0.05$ or $P_{CMH} < 0.05$ [only if $P_{BD} > 0.05$]) of the cant after correction for multiple testing (<i>P</i> _{CMH} of panels B and C) as well as genome	SNPs that we nd 693 cases; any/Austria at any/Austria at any/Austria at $\times 10^{-7}$ in the ontrols). Result for to NCBI's bilited in the capilication analypication analypication analysis of the odds ad SNPs in the	tre not panels A, B nd Italy, < 0.05 and 5 of all 100 uuid 36. A1 use - control sis (panels ratio of the si) of the t combined

Identification of risk loci in ALL subtype E Ellinghaus *et al*



905

Identification of risk loci in ALL subtype E Ellinghaus *et al*




Figure 1. Regional plots of the confirmed associations at *TP63, OR8U8,* on 8p21.3 and at *PTPRJ.* The regional plots of the negative decadic logarithm of the *P*-values obtained in the GWAS (panel A) are shown. Panel A was imputed with CEU haplotypes generated by the 1000 Genomes Project (August 2010 release) as reference. For the central lead SNP of each plot, the combined *P*-value of panels A and B (rs1945213, rs920590 and rs3942852) or panels A through C (rs17505102) is indicated. The magnitude of linkage disequilibrium (LD) with the central SNP measured by r^2 is reflected by the color of each SNP symbol (for color coding, see upper right corner of each plot). Recombination activity (in centimorgans (cM) per Mb) is depicted by a blue line. Positions are given as NCBI's build 36 coordinates. For details, see Table 1.

resides within a transcription factor binding site of BAF155 (SMARCC1), BAF170 (SMARCC2) and the proto-oncogene JunD assayed by CHiPseq in HeLa-S3 cells (UCSC Browser hg18). Hence, further experiments and analyses are required to elucidate the mechanism by which the SNPs rs17505102, rs1945213, rs3942852 and rs920590 affect the risk of ALL.

Associations with childhood ALL independent of *ETV6-RUNX1* subtype

In order to assess whether our findings were specifically associated with the ETV6-RUNX1-rearranged subtype, we genotyped the 20 top SNPs displayed in Table 1 in a second German replication cohort (panel D) consisting of 326 ETV6-RUNX1-negative childhood ALL cases. We analyzed these cases together with the same 1682 controls of panel B and obtained genotypes of 19 SNPs after quality control. Of the 19 SNPs only rs7738636 on chromosome 6q14.1 was significantly associated ($P = 2.55 \times 10^{-3}$). The combined analysis of the replication panels B/B_{extended} through D yielded only a marginally stronger association with $P_{CMH} = 1.42 \times 10^{-3}$ for rs7738636 (Supplementary Table S3). These results imply that rs7738636 might represent a susceptibility locus for ETV6-RUNX1-negative ALL patients. However, due to the small sample of ETV6-RUNX1-negative cases, our analysis does not have enough power to determine whether the newly identified loci distinguish ETV6-RUNX1-positive from -negative patients.

Associations of previously reported susceptibility-conferring SNPs Additionally, we genotyped the susceptibility-conferring SNPs identified by Papaemmanuil *et al.*¹¹ and Treviño *et al.*,¹²

respectively, in panels A through D in order to confirm the previously reported loci and as a positive control for our experiment. We observed genome-wide significant association ($P < 5 \times 10^{-8}$) for *IKZF1*, *DDC*, *ARID5B* and *CEBPE* in the combined sample (panels A–D) comprising 1438 cases and 2735 controls. Suggestive evidence of association (P < 0.05) was found for *SIAT7C*, 1q31.3 (rs6428370), *KCNMB2*, *PARD3* and *C12orf5* (Table 2).

DISCUSSION

In this study, we were able to identify attractive, novel risk loci for ALL, even with a small screening sample – compared with other GWAS studies and diseases – of only 419 patients. This success might be due to the exclusive selection of patients with the homogenous phenotype of *ETV6–RUNX1*-rearranged childhood ALL. Given their interesting biological function, we below discuss the relevance of *TP63* and *PTPRJ* in ALL disease etiology.

The *TP63* gene – a member of the *TP53* gene family – codes for p63 which has essential roles in embryonic development. *TP63* contains two transcriptional start sites leading to p63 isoforms either containing (TAp63) or lacking (\triangle Np63) the trans-activation domain.²¹ *TP63*-null mice die cancer-free within a few hours of birth, showing severe loss of limbs and a wide range of epithelial structures including skin, prostate, breast and urothelia.^{22,23} This suggests that p63 acts as an important regulator of stemness in developing epithelia.^{24,25} In humans, *TP63* mutations are associated with ectodermal dysplasia, cleft lip or palate and limb malformations, but not with a higher tumor incidence.^{21,26} In line with these observations, the *TP63* coding region is found only

906

	A1 Panel A Germany A2 ETV6-RUNX1 pos. 474 controls	Panel B Germany ETV6 - RUNX1 pos. 1682 controls	Panel C Italy ETV6-RUNX1 pos. 579 controls		Panel A + B + C Combined analysis ETV6 - RUNX1 pos. 2735 controls	- C Jysis Is	Panel D Germany ETV6 - RUNX1 neg.	FT F	Panel A + B + C + D Combined analysis ETV6 - RUNX1 pos. + neg. 2735 controls	. + D ysis + neg.
	AF _{A1} contr. AF _{A1} contr.	AF _{A1} contr. AF _{A1} case	AF _{A1} contr. AF _{A1} contr.	P _{CMH}	P _{BD}	OR (95% CI)	AF_{A1} case	Рсмн	P _{BD}	OR (95% CI)
				5				ł		
rs6964823 P IKZF1 G	0.47	0.49 0.44	0.51 0.47	$1.14 imes 10^{-04}$	0.85	0.82 (0.74-0.91)	- 0.44	$5.56 imes 10^{-05}$	0.93	0.83 (0.75 - 0.91)
rs4132601 G		0.27	0.26	$1.65 imes 10^{-10}$	0.58	1.42 (1.27 - 1.58)	- 0.35	$8.26 imes 10^{-13}$	0.65	1.43 (1.30 - 1.58)
rs6944602 P	A 0.22	0.19	0.22	$\textbf{1.99}\times\textbf{10}^{-07}$	0.39	1.42 (1.25 - 1.63)	 2 - 0	$\textbf{3.10}\times\textbf{10}^{-\textbf{09}}$	0.42	1.42 (1.27 - 1.60)
rs3779084 C		0.20	0.16	$2.36 imes 10^{-05}$	0.17	1.30 (1.15 - 1.46)		$2.44 imes 10^{-06}$	0.19	1.30 (1.17 - 1.46)
DDC 1 rs880028 C		0.23 0.20	0.22 0.16	$2.91 imes 10^{-05}$	0.09	1.29 (1.15 - 1.46)	0.25 -	$\mathbf{8.69 imes 10^{-06}}$	0.09	1.28 (1.15 - 1.43)
DDC 1 rs7809758 G	0.25	0.23 0.34	0.22 0.32	$2.04 imes 10^{-05}$	0.27	1,29 (1,15 - 1,45)	0.24 -	$1.48 imes 10^{-07}$	0.40	1.32 (1.19 - 1.46)
		0.39	0.40				0.41			
rs7073837 P	0.40	0.37	0.43	$7.76 \times 10^{-0.7}$	0.85	1.29 (1.17 - 1.42)	-0.46	$1.50 imes 10^{-08}$	0.75	1.30 (1.19 - 1.43)
5		0.53	0.49	$\textbf{8.75}\times\textbf{10}^{-07}$	0.73	0.78 (0.70-0.86)	-	$\textbf{8.95}\times \textbf{10}^{-\textbf{09}}$	0.88	0.76 (0.70-0.84)
ARID5B C rs7089424 G		0.46 0.32	0.42 0.38	$9.05 imes 10^{-10}$	0.30	1.38 (1.24-1.53)	0.44	$1.98 imes 10^{-13}$	0.17	1.42 (1.30 - 1.56)
ARID5B T rs2239633 T		0.42 0.50	0.44 0.43	$1.53 imes 10^{-08}$	0.51	0.75 (0.67 - 0.83)	0.43 -	$4.00 imes 10^{-10}$	0.50	0.74 (0.68-0.82)
. 0	0.42	0.41	0.38				0.41			
;				03 <u>10</u> 13				03	Ì	
rs108/38/6 I SIAT7C C	0.15	0.19 0.19	0.18 0.22	8.14 × 10 ⁻²	0./4	(95.1 - 30.1) 02.1	- 0.17	5.47 × 10	0./1	(46.1 - c0.1) 91.1
rs6428370 G		0.31	0.36	0.14	0.41	1.08 (0.97 - 1.20)	- 0.35	0.03	0.63	1.12 (1.01 - 1.23)
- rs7554607 G		0.43	0.46	0.12	0.32	1.08 (0.98 - 1.20)	-	0.34	0.18	1.05 (0.95 - 1.15)
RYR2 A	0.48	0.41	0.51	0.71	047	1 03 (0 00 - 1 17)	0.41	0.76	0.25	0.08 (0.87 - 1.11)
		0.19	0.19	- 7:0	74.0		0.16	0.00	12.0	(11.1 - 10.0) 00.0
rs12621643 T kCNF4 G	0.29	0.28	0.42	0.14	2.16×10^{-03}	1.08 (0.97 - 1.20)	-	0.06	1.81×10^{-03}	1.10 (1.00 - 1.21)
rs9290663 7		0.14	0.23	0.02	0.70	1.18 (1.03 - 1.34)		$\textbf{6.90}\times\textbf{10}^{-03}$	0.74	1.18 (1.05 - 1.33)
rs11155133 G	6 0.01 0.01	0.01	0.01	0.27	0.37	1.32 (0.81 - 2.14)	- 100	0.28	0.41	1.28 (0.81 - 2.03)
rs11978267 G		0.27 0.34	0.25 0.33	$8.74 imes 10^{-11}$	0.70	1.43 (1.28 - 1.59)	- 0.35	$1.07 imes 10^{-12}$	0.73	1.44 (1.30 - 1.59)
rs2242041 G		0.09	0.05	$7.51 imes 10^{-03}$	0.38	1.26 (1.06 - 1.50)	- 012	$8.47 imes 10^{-04}$	0.48	1.30 (1.11 - 1.52)
rs2167364 G		0.31	0.29	$2.33 imes 10^{-07}$	0.35	1.32 (1.19-1.46)	- 037	$1.73 imes 10^{-08}$	0.36	1.32 (1.20 - 1.45)
rs563507 F		0.04	0.07	0.047	0.65	1.25 (1.00-1.55)	-	0.046	0.73	1.23 (1.00-1.51)
R	0.51	0.046	0.08 0.51	$\textbf{2.07}\times\textbf{10}^{-05}$	0.86	1.24 (1.12-1.37)	0.05	$1.39 imes 10^{-06}$	0.94	1.25 (1.14-1.37)
rs10821936 C		0.31	0.37	1.25×10^{-11}	0.56	1.42 (1.29-1.58)		$\textbf{4.06} \times \textbf{10}^{-15}$	0.42	1.46 (1.33 - 1.60)
		0.42	0.44	500	020		0.42	2000	100	
rsiu849033 G C12orf5 A	0.01	0.03	0.03	10.0	60.0	(75.2 - 11.1) 20.1	- 0.01	0.046	0.91	1.43 (1.00 - 2.02)
2						(11 1 00 0) 00 1				

Identification of risk loci in ALL subtype E Ellinghaus *et al*

_ 90



Table 2 (Continued)	tinued)											
Chr position (bp)	dbSNP ID Gene name	A1 A2	Panel A Germany ETV6-RUNX1 pos. 474 controls 419 cases	Panel B Germany ETV6-RUNX1 pos. 1682 controls 406 cases	Panel C Italy ETV6-RUNX1 pos. 579 controls 287 cases		Panel A + B + C Combined analysis ETV6-RUNX1 pos. 2735 controls 1112 cases	+ C Julysis pos. Sis	Panel D Germany ETV6 - RUNX1 neg. 326 cases	Ę	Panel A + B + C + D Combined analysis ETV6-RUNX1 pos. + neg. 2735 controls 1438 cases	C + D alysis - : + neg. s
			AF _{A1} contr. AF _{A1} case	AF _{A1} contr. AF _{A1} case	AF _{A1} contr. AF _{A1} case	P _{CMH}	P_{BD}	OR (95% CI)	– AF _{A1} case	Рсмн	P_{BD}	OR (95% CI)
18	rs1879352	σ	0.15	0.16	0.17	0.75	0.09	0.98 (0.85 - 1.12)	•	0.83	0.11	0.99 (0.87 - 1.12)
2 488 054	ı	۲	0.14	0.14	0.19				0.15			
19	rs2191566	0	0.29	0.29	0.34	0.35	0.04	0.95 (0.85 - 1.06)		0.88	0.01	0.99 (0.90 - 1.10)
49 203 229 19	ZNF230 rs6509133	K U	670 670	0.30	0.35	0.46	0.04	0.96 (0.86 - 1.07)	0.33	0.98	0.02	1.00 (0.91 - 1.10)
49214753	ZNF230	F	0.29	0.32	0.30				0.33			
Abbreviations: Treviño <i>et al.</i> , w NCBl's build 36 (P_{CMH}) and corr shows the asyr Significant P -va shading.	AF, allele freque Re genotyped i. The rare allel hibined odds ra nptotic P-value ilues (P _{CMH} < 0.	Jency; the res le is A1 atios (O as of a .05 [onl	Abbreviations: AF, allele frequency; Chr, chromosome; Cl, confidence inte Treviño <i>et al.</i> , we genotyped the respective 28 SNPs in the panels A throu NCBI's build 36. The rare allele is A1 while A2 denotes the common allel (P_{CMH}) and combined odds ratios (OR) of the Cochran - Mantel - Haenszel shows the asymptotic <i>P</i> -values of a Breslow - Day test for heterogeneity. Significant <i>P</i> -values ($P_{CMH} < 0.05$ [only if $P_{BD} > 0.05$]) are highlighted in bol shading.	Cl, confidence inter the panels A throug the common allele. Mantel - Haenszel t for heterogeneity. A highlighted in bold	Abbreviations: AF, allele frequency; Chr, chromosome; Cl, confidence interval; OR, odds ratio; SNP, single-nucleotide polymorphism. In order to confirm the associated SNPs reported by Papaemmanuil <i>et al.</i> and Treviño <i>et al.</i> , we genotyped the respective 28 SNPs in the panels A through D. SNPs are ranked according to their chromosomal position and to the respective study. Nucleotide positions (position (bp)) refer to NEBI's build 36. The rare allele is A1 while A2 denotes the common allele. The respective allele frequencies are listed for allele A1 in controls and cases, respectively, (AF _{A1} contr./AF _{A1} case). Combined <i>P</i> -values (<i>P</i> _{CMH}) and combined odds ratios (OR) of the Cochran - Mantel - Haenszel test statistic (one degree of freedom) for the case-control analysis of panels A through D are listed. Column <i>P</i> _{BD} shows the asymptotic <i>P</i> -values of a Breslow -Day test for heterogeneity. A significant <i>P</i> _{BD} indicates a significant heterogeneity between replication panels in terms of the disease association. Significant <i>P</i> -values (<i>P</i> _{CMH} <0.05 [only if <i>P</i> _{BD} >0.05]) are highlighted in bold. SNP associations that reached genome-wide significance in the combined panels A through D are highlighted by grey shows the asymptotic <i>P</i> -values (<i>P</i> _{CMH} <0.05 [only if <i>P</i> _{BD} >0.05]) are highlighted in bold. SNP associations that reached genome-wide significance in the combined panels A through D are highlighted by grey shading.	iNP, single-nucl a according to e frequencies a gree of freedon cates a signific nat reached ge	leotide polym their chromo are listed for a n) for the case cant heteroge nome-wide si	torphism. In order the somal position and somal position and lilele A1 in controls allele A2 in control analysis of -control analysis of the sometry between replinent the cognificance in	o confirm the associ to the respective str and cases, respectiv panels A through C cation panels in ter mbined panels A th	ated SNPs repudy. Nucleotid udy. Nucleotid (AF _{A1} cont and panels A ms of the odd rough C or A t	orted by Papa e positions (po tr/AF _{A1} case). through D are s ratio of the hrough D are	emmanuil <i>et al.</i> and sition (bp)) refer to Combined <i>P</i> -values e listed. Column P_{BD} disease association. highlighted by grey

rarely mutated in human cancers.^{27,28} To date, recurrent somatic TP63 mutations have only been described for non-small cell lung cancer as well as chronic myeloid leukemia^{28,29} and *TP63* germline genetic variation (rs710521) has only been associated with urinary bladder cancer, so far.³⁰ However, mice heterozygous for TP63 mutations develop malignant lesions, demonstrating that TP63 can act as a tumor suppressor and mice heterozygous for mutations in both TP53 and TP63 display higher tumor burden and metastasis compared with mice only heterozygous for TP53 mutations.³¹ Of particular interest to our study, TAp63 was described to be involved in an antiapoptotic pathway regulating normal B and chronic lymphocytic leukemia cell survival in a CD74-dependant manner.^{32,33} In chronic lymphocytic leukemia, TAp63 expression upregulates VLA-4 integrin expression leading to augmented migration and homing of chronic lymphocytic leukemia cells to the bone marrow.³³ Also, it was found that thymomas and certain B-cell lymphomas express high levels of TP63, suggesting a role of TP63 in these cancers.³⁴

PTPRJ is a receptor type protein tyrosine phosphatase involved in the regulation of cellular processes including cell growth, differentiation, mitotic cycle and oncogenic transformation. Somatic mutations of *PTPRJ* have been described in a wide spectrum of cancers like thyroid carcinomas, colon cancer, breast and lung cancer.³⁵⁻³⁸ Furthermore, a specific *PTPRJ* haplotype was shown to be associated with the risk of breast cancer demonstrating that common *PTPRJ* variants may act as breast cancer susceptibility alleles.³⁹ Interestingly, the *PTPRJ* gene is expressed at high levels in hematopoietic cells.^{35,37,40} Of particular interest to the results reported in our study, mice with a constitutively deleted transmembrane domain allele of *PTPRJ* display a partial peripheral B-cell developmental block.⁴¹ Heterozygous mice do not show any notable phenotype.

Although the current knowledge on *TP63* and *PTPRJ* may provide some evidence for their role in tumorigenesis as well as B-cell development and/or maintenance, more precise mechanisms how germline genetic variation at the *TP63* and *PTPRJ* loci may modulate susceptibility to precursour B-cell leukemia remain speculative and underscore the need for functional studies.

Apart from our novel findings, our study could clearly confirm the association of childhood ALL with the four previously published susceptibility loci *IKZF1*, *DDC*, *ARID5B* and *CEBPE*. Nominal significant *P*-values (P < 0.05) were obtained for *SIAT7C*, 1q31.3, *KCNMB2*, *PARD3* and *C12orf5*. Although our study panel had more than 80% power to detect all of the SNPs/loci published by Papaemmanuil *et al.*¹¹ and Trevino *et al.*,¹² respectively, we could not replicate the loci *RYR2*, *OR2C3*, *KCNE4*, 6q24.1, *KRTHB5*, 18p11.32 and *ZNF230*, which therefore require further investigations.

Overall, our findings demonstrate that germline genetic variation can specifically contribute to the risk of specific ALL subtypes, in this case *ETV6-RUNX1*-positive childhood ALL. Our results also suggest that germline genetic variation can act as a risk factor for childhood ALL in general or functions restricted to specific subtypes, only.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

The authors wish to thank all ALL patients, families and physicians for their cooperation. Also, we wish to thank T Wesse, T Henke, M Wittig, R Vogler, L Tittmann and B Fedders for expert technical help. We are grateful to C Becker, R Niemiec and C Kluck for genotyping the samples of GWAS panel A. Prof Dr T Wienker and Dr M Steffens (IMBIE, University of Bonn) are acknowledged for performing the quality control of the GWAS control data set. This study was supported by the German Ministry of Education and Research (BMBF) through the National Genome Research Network (NGFN), the popgen biobank, the Federal Radiation Protection Agency (project no. 3609530013), the Deutsche Krebshilfe and the Madeleine

Schickedanz Kinderkrebs-Stiftung. The project received infrastructure support through the DFG excellence cluster 'Inflammation at Interfaces'. This study was conducted within the frame of the International BFM Study Group.

AUTHOR CONTRIBUTIONS

EE, AF and GR performed the SNP selection, genotyping, data analysis and resequencing. EE prepared figures and tables. DE prepared regional plots and helped with data analysis and quality control. AE, RH, AN and MZ helped with data analysis. PN coordinated the Affymetrix chip genotyping. M St, G Car and M Sch coordinated the recruitment and collected the phenotype data. GK, G Caz, JT, OC, HC, RPG, BM, TB, CF and MH recruited the additional case - control panels. AT-S, GK, MG, G Caz, and RPG were involved in phenotypic characterization of cases. AF, BH, G Car, M Sch, M St and SS designed and supervised the experiment. EE, M St and AF wrote the manuscript. All authors approved the final manuscript.

URLs

SNPexp²⁰ v1.1:

http://app3.titan.uio.no/biotools/tool.php?app = snpexp

R script for Regional Association Plots:

 $\label{eq:http://www.broadinstitute.org/science/projects/diabetes-genetics-initiative/plotting-genome-wide-association-results$

1000 Genomes data:

http://www.sph.umich.edu/csg/abecasis/MACH/download/

REFERENCES

- 1 Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006; 354: 166-178.
- 2 Stanulla M, Schrappe M. Treatment of childhood acute lymphoblastic leukemia. Semin Hematol 2009; 46: 52-63.
- 3 Redaelli A, Laskin BL, Stephens JM, Botteman MF, Pashos CL. A systematic literature review of the clinical and epidemiological burden of acute lymphoblastic leukaemia (ALL). *Eur J Cancer Care (Engl)* 2005: 14: 53-62.
- 4 Linabery AM, Ross JA. Trends in childhood cancer incidence in the US (1992 - 2004). *Cancer* 2008; **112**: 416 - 432.
- 5 Howard SC, Metzger ML, Wilimas JA, Quintana Y, Pui CH, Robison LL *et al.* Childhood cancer epidemiology in low-income countries. *Cancer* 2008; **112**: 461 472.
- 6 Belson M, Kingsley B, Holmes A. Risk factors for acute leukemia in children: a review. *Environ Health Perspect* 2007; **115**: 138-145.
- 7 Eden T. Aetiology of childhood leukaemia. Cancer Treat Rev 2010; 36: 286-297.
- 8 Teitell MA, Pandolfi PP. Molecular genetics of acute lymphoblastic leukemia. Annu Rev Pathol 2009; **4**: 175 - 198.
- 9 Mullighan CG, Downing JR. Genome-wide profiling of genetic alterations in acute lymphoblastic leukemia: recent insights and future directions. *Leukemia* 2009; 23: 1209 - 1218.
- 10 Greaves M. Darwin and evolutionary tales in leukemia. The Ham-Wasserman Lecture. Hematol Am Soc Hematol Educ Program 2009; 2009: 3 - 12, PMID: 20008176.
- 11 Papaemmanuil E, Hosking FJ, Vijayakrishnan J, Price A, Olver B, Sheridan E *et al.* Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. *Nat Genet* 2009; **41**: 1006 - 1010.
- 12 Trevino LR, Yang W, French D, Hunger SP, Carroll WL, Devidas M et al. Germline genomic variants associated with childhood acute lymphoblastic leukemia. *Nat Genet* 2009; **41**: 1001 - 1005.
- 13 Prasad RB, Hosking FJ, Vijayakrishnan J, Papaemmanuil E, Koehler R, Greaves M *et al.* Verification of the susceptibility loci on 7p12.2, 10q21.2, and 14q11.2 in precursor B-cell acute lymphoblastic leukemia of childhood. *Blood* 2010; **115**: 1765 1767.
- 14 Krawczak M, Nikolaus S, von Eberstein H, Croucher PJ, El Mokhtari NE, Schreiber S. PopGen: population-based recruitment of patients and controls for the analysis of complex genotype-phenotype relationships. *Community Genet* 2006; **9**: 55-61.
- 15 Dupont WD, Plummer WD. PS power and sample size program available for free on the Internet. *Controlled Clin Trials* 1997; **18**: 274.
- 16 Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* 2007; **81**: 559-575.
- 17 Browning BL, Browning SR. A unified approach to genotype imputation and haplotype-phase inference for large data sets of trios and unrelated individuals. *Am J Hum Genet* 2009; 84: 210-223.
- 18 Stranger BE, Nica AC, Forrest MS, Dimas A, Bird CP, Beazley C et al. Population genomics of human gene expression. *Nat Genet* 2007; **39**: 1217-1224.

- 19 Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 2001; 29: 308-311.
- 20 Holm K, Melum E, Franke A, Karlsen TH. SNPexp a web tool for calculating and visualizing correlation between HapMap genotypes and gene expression levels. BMC Bioinformatics 2010; 11: 600.
- 21 Collavin L, Lunardi A, Del Sal G. p53-family proteins and their regulators: hubs and spokes in tumor suppression. *Cell Death Differ* 2010; **17**: 901 911.
- 22 Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. p63 is a p53 homologue required for limb and epidermal morphogenesis. *Nature* 1999; **398**: 708-713.
- 23 Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT *et al.* p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. *Nature* 1999; **398**: 714-718.
- 24 Senoo M, Pinto F, Crum CP, McKeon F. p63 Is essential for the proliferative potential of stem cells in stratified epithelia. *Cell* 2007; **129**: 523-536.
- 25 Su X, Paris M, Gi YJ, Tsai KY, Cho MS, Lin YL *et al.* TAp63 prevents premature aging by promoting adult stem cell maintenance. *Cell Stem Cell* 2009; **5**: 64-75.
- 26 Celli J, Duijf P, Hamel BC, Bamshad M, Kramer B, Smits AP *et al*. Heterozygous germline mutations in the p53 homolog p63 are the cause of EEC syndrome. *Cell* 1999; **99**: 143 153.
- 27 Hagiwara K, McMenamin MG, Miura K, Harris CC. Mutational analysis of the p63/ p73L/p51/p40/CUSP/KET gene in human cancer cell lines using intronic primers. *Cancer Res* 1999; **59**: 4165-4169.
- 28 Sunahara M, Shishikura T, Takahashi M, Todo S, Yamamoto N, Kimura H et al. Mutational analysis of p51A/TAp63gamma, a p53 homolog, in non-small cell lung cancer and breast cancer. Oncogene 1999; 18: 3761-3765.
- 29 Yamaguchi H, Inokuchi K, Sakuma Y, Dan K. Mutation of the p51/p63 gene is associated with blastic crisis in chronic myelogenous leukemia. *Leukemia* 2001; 15: 1729-1734.
- 30 Kiemeney LA, Sulem P, Besenbacher S, Vermeulen SH, Sigurdsson A, Thorleifsson G *et al.* A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. *Nat Genet* 2010; **42**: 415-419.
- 31 Flores ER, Sengupta S, Miller JB, Newman JJ, Bronson R, Crowley D et al. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 2005; 7: 363-373.
- 32 Lantner F, Starlets D, Gore Y, Flaishon L, Yamit-Hezi A, Dikstein R *et al.* CD74 induces TAp63 expression leading to B-cell survival. *Blood* 2007; **110**: 4303 4311.
- 33 Binsky I, Lantner F, Grabovsky V, Harpaz N, Shvidel L, Berrebi A et al. TAp63 regulates VLA-4 expression and chronic lymphocytic leukemia cell migration to the bone marrow in a CD74-dependent manner. J Immunol 2010; 184: 4761 - 4769.
- 34 Di Como CJ, Urist MJ, Babayan I, Drobnjak M, Hedvat CV, Teruya-Feldstein J et al. p63 expression profiles in human normal and tumor tissues. *Clin Cancer Res* 2002; 8: 494 - 501.
- 35 Mita Y, Yasuda Y, Sakai A, Yamamoto H, Toyooka S, Gunduz M *et al.* Missense polymorphisms of PTPRJ and PTPN13 genes affect susceptibility to a variety of human cancers. *J Cancer Res Clin Oncol* 2010; **136**: 249-259.
- 36 Iuliano R, Le Pera I, Cristofaro C, Baudi F, Arturi F, Pallante P et al. The tyrosine phosphatase PTPRJ/DEP-1 genotype affects thyroid carcinogenesis. Oncogene 2004; 23: 8432-8438.
- 37 Ruivenkamp CA, van Wezel T, Zanon C, Stassen AP, Vlcek C, Csikos T *et al.* Ptprj is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers. *Nat Genet* 2002; **31**: 295-300.
- 38 Ruivenkamp C, Hermsen M, Postma C, Klous A, Baak J, Meijer G et al. LOH of PTPRJ occurs early in colorectal cancer and is associated with chromosomal loss of 18q12-21. Oncogene 2003; 22: 3472-3474.
- 39 Lesueur F, Pharoah PD, Laing S, Ahmed S, Jordan C, Smith PL *et al.* Allelic association of the human homologue of the mouse modifier Ptprj with breast cancer. *Hum Mol Genet* 2005; **14**: 2349-2356.
- 40 de la Fuente-Garcia MA, Nicolas JM, Freed JH, Palou E, Thomas AP, Vilella R et al. CD148 is a membrane protein tyrosine phosphatase present in all hematopoietic lineages and is involved in signal transduction on lymphocytes. *Blood* 1998; **91**: 2800 - 2809.
- 41 Zhu JW, Brdicka T, Katsumoto TR, Lin J, Weiss A. Structurally distinct phosphatases CD45 and CD148 both regulate B cell and macrophage immunoreceptor signaling. *Immunity* 2008; 28: 183-196.

This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/

Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)